Avandia Risks May Cost Glaxo $300 Million in Alzheimer’s Sales

Glaxo Smith Kline Plc is likely to delay marketing its troubled Avandia diabetes pill as an Alzheimer’s disease treatment because patients are reluctant to volunteer for research studies.
Glaxo, Europe’s largest drugmaker, has lost more than 33 percent of Avandia’s $3.3 billion in annual sales since a report in May tied the pill to heart attacks. Glaxo is trying to transform the drug into an Alzheimer’s therapy after a preliminary study in 2005 suggested that Avandia may improve memory in some patients.

Source: Bloomberg.com. Please read the entire story at www.bloomberg.com